Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DRP-104 |
| Synonyms | |
| Therapy Description |
Sirpiglenastat (DRP-104) is the prodrug form of glutamine antagonist, which potentially modulates immune response and inhibits tumor growth (J Immunother Cancer. 2019; 7(Suppl 1): 282, Abs nr: P497). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DRP-104 | DRP 104|DRP104|Sirpiglenastat | Sirpiglenastat (DRP-104) is the prodrug form of glutamine antagonist, which potentially modulates immune response and inhibits tumor growth (J Immunother Cancer. 2019; 7(Suppl 1): 282, Abs nr: P497). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07249372 | Phase II | DRP-104 | DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT04471415 | Phase Ib/II | DRP-104 Atezolizumab + DRP-104 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Terminated | USA | ESP | DEU | 2 |